Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Learn more about:
Related Clinical Trial
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer Metabolic Stress-induced Exercise to Prevent Loss of Muscle Mass in Patients With Pancreatic and Biliary Tract Cancer The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer A Study of ABL001 in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy Predicting Disease Progression and/or Recurrence in Cancer Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis A Phase 1/2 Study of SC-43 in Combination With Cisplatin The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Unresectable Biliary Tract Cancer. A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer A Trial of SHR1258 in Patients With Biliary Tract Cancer Perception Prognosis, Goals of Treatment, and Communication IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Tremelimumab With Chemoembolization or Ablation for Liver Cancer Preoperative Nutritional Support in Malnutritional Cancer Patients Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions Early Palliative Care on Quality of Life of Advanced Cancer Patients Patient Activation Through Counseling, Exercise and Mobilization Extracellular RNA Markers of Liver Disease and Cancer X-MAS Biliary Study With Covered Biliary Stent A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors GTX Regimen for Biliary Cancers Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer FOLFIRINOX for 2nd-line Treatment of BTC Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Trastuzumab in HER2-positive Biliary Tract Cancer Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase Second Line Therapy in Advanced Biliary Tract Cancer Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer. Case Series Study of Biliary Tract Cancer Patients in Japan GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer Molecular Profiling of Advanced Biliary Tract Cancers MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer Allogeneic NK Cell (“SMT-NK”) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer Vessel Resection and Reconstruction of Biliary Tract Cancers Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) NGS as the First-line Treatment in Advanced Biliary Tract Cancer Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Molecular Profiling of Advanced Biliary Tract Cancers

Brief Title

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Official Title

Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System

Brief Summary

      To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated
      patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response
      rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III
      clinical trial.
    

Detailed Description

      Human epidermal growth factor receptor 2, (HER2) is overexpressed /amplified in multiple
      carcinomas, for example, gastric cancer(GC), gastroesophageal junction
      adenocarcinoma(GEJA),and breast cancer.And HER2 is closely related to tumor proliferation
      &metastases.About 90% Chinese esophagus cancer are squamous cell origin. The reported HER2
      overexpression ranged from 5-30%, Beijing cancer hospital reported an 11% positive rate. The
      variety of HER2 positive rate may because of the absence of standard HER2 testing criteria.
      The current treatment for metastatic Esophageal squamous Cell Carcinoma (ESCC) is not
      satisfactory. Fluorouracil and platinum are considered as first line standard of care (SOC)
      with a 20-30% RR and 7-9 months overall survival (OS). In second line setting, there is no
      SOC in china. And the efficacy is not satisfactory. Esophageal adenocarcinoma has a higher
      HER2 positive rate of 14%, but no data reported of using trastuzumab in these patients in
      China. Biliary tract cancer (BTC), including intrahepatic/extrahepatic cholangiocarcinoma and
      Gallbladder cancer (GBC) is very aggressive, total 5y survival is less than 5% for
      unresectable patients. GBC is account for approximately 2/3 of BTC, and it's estimated the
      incidence in china is 52800 and the mortality is 40700 in 2015. Most patients are diagnosed
      in advanced stage and lose the opportunity of surgery. However, there is no SOC for
      unresectable BTC, gemcitabine plus platinum provided a 30% RR and 10 month OS. In second line
      treatment, no differences were seen between various experimental agents. The reported HER2
      positive rate range from 5.1% to 57% in biliary duct cancer and 4.7% to 64% in GBC.
      Researchers reported her2 amplification is related to tumor stage and lymph nodes metastasis
      in 221 BTC patients. Another study reported a 16.6% positive rate and worse prognosis with a
      sample size of 230 GBC patients. Meanwhile, HER2 pathway mutation rate reached 37%. All imply
      that BTC may be the potential anti HER therapy population. Besides, other digestive system
      tumor has low HER2 positive rate (Small intestinal cancer 0.9-3%; hepatocellular carcinoma
      2.4%; Pancreatic cancer 3%; etc.). However, the patient pool is large and has no SOC in
      second Line. Whether these HER2 + patients can gain benefit form anti- her treatment is worth
      investigating. In 2016 American Society of Clinical Oncology (ASCO), a study reported that
      using trastuzumab and pertuzumab combination, 35% metastatic colorectal cancer (CRC) and 50%
      BTC patients who heavily pretreated had objective response. However, china doesn't have
      studies for these patients. .

      The concurrent basket trial will explore the efficacy and safety of trastuzumab with
      chemotherapy in Chinese patients of pretreated, HER2 positive, relapse or metastatic
      carcinoma of digestive system.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Response Rate(RR) for each cohort in intent to treat (ITT) population

Secondary Outcome

 Disease control rate

Condition

Targeted Therapy

Intervention

chemotherapy in combination with trastuzumab for arm1

Study Arms / Comparison Groups

 GI tumor beyond CRC, ESCC, BTC,GC&GEJA
Description:  HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

100

Start Date

July 1, 2017

Completion Date

September 2021

Primary Completion Date

July 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Signed informed consent.

          -  Male and female patients aged from 18 to 75 years

          -  Histologically confirmed Colorectal cancer,Esophagus squamous cell carcinoma, biliary
             tract cancer, and digestive system tumor beyond CRC and GC&GEJA with the following
             specifications:

               -  genetic testing conformed KRAS/NRAS/BRAF all wild type for colorectal cancer

               -  Detection of a carcinoma with HER2 3+ (IHC) or HER2 2+ (IHC) with amplification
                  proven by fluorescence in situ hybridization(FISH), silver in situ
                  hybridization(SISH) or chromogenic in situ hybridization(CISH) using gastric
                  cancer criteria by an accredited local pathologist.

               -  Relapse or metastatic diseases, at least one measurable lesion according to
                  RECIST 1.1, anticipated survival ≥ 12 weeks.

               -  ECOG Performance status 0-1.

               -  Patients who failed at least first line systemic therapy.

               -  Adequate organ function as determined by the following laboratory results:

               -  Absolute neutrophil count ≥1500 cells/mm3,

               -  Platelet count ≥ 90,000 cells/mm3,

               -  Hemoglobin ≥9.0 g/dL

               -  Total bilirubin ≤ 1.5 upper limit of normal (ULN).

               -  serum glutamate oxaloacetate transaminase(SGOT,AST), serum glutamate pyruvate
                  transaminase(SGPT,ALT) < 2.5 ULN without liver metastases; < 5 ULN with liver
                  metastases.

               -  serum creatinine < 1.5

               -  ULN OR creatinine clearance ≥ 40 mL/ min.

          -  If able to reproduce, patients must be willing to use highly effective methods of
             contraception during treatment and for 7 months after the end of treatment.

        Exclusion Criteria:

          -  Known hypersensitivity against treatment regimen.

          -  Baseline left ventricular ejection fraction(LVEF) < 50% (measured by echocardiography
             or MUGA).

          -  Previous anti-her treatment.

          -  Immune therapy, biological therapy or any participation in clinical trial in previous
             two weeks.

          -  Surgery and not recovered in previous three weeks

          -  Clinical evidence of brain metastases, or uncontrolled epilepsy.

          -  Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly
             controlled diabetes.

          -  Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,
             or basal cell carcinoma.

          -  Clinically significant active coronary heart disease, cardiomyopathy or congestive
             heart failure, New York Heart Association(NYHA) III-IV; poorly controlled hypertension
             (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular
             heart disease; unstable angina pectoris, myocardial infarction or high risk
             uncontrollable arrhythmias.

          -  Long term or high dose corticosteroids administration ( inhalation or short term oral
             administration for antiemesis and orexigenic is allowed)

          -  Patients of legally incapacity or of medical and ethical reasons not fit for study.

          -  Pregnant or lactating, or intending to become pregnant during the study.

          -  Jaundice, ascites, and / or alkaline phosphatase ≥3 × ULN; and / or ≥3 grade (CTC-AE)
             of persistent proteinuria, urinary protein / creatinine ratio> 3.5g / 24 hours or
             renal failure need blood or peritoneal dialysis.

          -  Presence of > grade 2(CTC-AE) persistent infection; unhealed wounds, ulcer or
             fracture, or patients with a history of organ transplant.

          -  Evidence of coagulation disorders. Like presence ≥grade 3 (CTC-AE) bleeding events.

          -  Known HIV or hepatitis B virus(HBV), hepatitis C virus(HCV) infection.

          -  Any > grade 1 unresolved toxicity due to previous treatment (CTC-AE), except for
             alopecia, anemia and hypothyroidism).

          -  Not suitable for the study evaluated by investigators

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency.

          -  History of exposure to the following cumulative doses of anthracyclines:

               -  Doxorubicin > 500 mg/m2 OR Epirubicin > 720 mg/m2.

                    -  If another anthracycline or more than one anthracycline has been used, then
                       the cumulative dose must not exceed the equivalent of 500 mg/m2 doxorubicin.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Lin Shen, Master, 86-10-8819-6561, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT03185988

Organization ID

CGOG2006


Responsible Party

Sponsor-Investigator

Study Sponsor

Shen Lin


Study Sponsor

Lin Shen, Master, Principal Investigator, Director


Verification Date

July 2019